Penn State Research Uncovers Immune Mechanism in Heart Failure Progression

Heart failure occurs when the heart's muscle is weakened or injured, impairing its ability to pump sufficient blood. This condition, where heart function falls below 40%, affects an estimated 6.7 million individuals over 20 in the United States, according to the Centers for Disease Control and Prevention. Approximately 50% of patients with heart failure die within five years of diagnosis, and no current cure halts its progression.

A critical barrier to developing new treatments has been a limited understanding of the underlying mechanisms driving progressive cardiac dysfunction.

Shyam Bansal, an associate professor of medicine at Penn State College of Medicine and vice chair for basic science research at Penn State Heart and Vascular Institute, highlighted that existing medications for heart failure have not altered disease progression over the past 25 to 35 years.

Immune Cells Over-Activated in Failing Hearts

Now, a significant finding from Bansal's research team at Penn State College of Medicine offers new insights. The team identified that helper T cells, a type of immune cell typically involved in wound healing and infection combat, become over-activated in failing human hearts, contributing to damage.

This observation marks the first instance of T cell activation being noted in human hearts. The findings indicate the pivotal role of inflammation and immune dysfunction in heart failure development.

Suggesting New Therapeutic Targets

Crucially, this discovery also suggests potential therapeutic targets for designing novel drugs to treat heart failure. The team's research was published in the Journal of Molecular and Cellular Cardiology.